Detailansicht

Wissensnetz

Person

Carmen Loquai (1974-)

Hautärztin

Name	Carmen Loquai
Zeit	1974- (Lebensdaten)
Ort	Deutschland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Dr. med. (an der Medizinischen Fakultät der Universität Bonn) (2000)
Beruf	Hautärztin (charakteristischer Beruf)
Variante	Carmen A. Loquai Carmen Angelika Loquai
Weitere Angaben	Habil.-Schr. für das Fach Dermatologie und Venerologie der Universität Mainz, 2014
Datensatztyp	Person
GND-Nummer	122252500
Datensatz-ID	122252500
Beteiligt an alle anzeigen Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective Second opinion and self‐efficacy in German skin cancer patients Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG eHealth literacy in German skin cancer patients Evaluation of 2‑methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma Gibt es eine Überbehandlung von Melanompatienten am Ende ihres Lebens? : : Ergebnisse einer multizentrischen Studie an 193 Melanompatienten = Is there an overtreatment of melanoma patients at the end of their life? : results of a multicenter study on 193 <br>melanoma patients Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021 Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis Erfassung der psychosozialen Belastung und Lebensqualität beim malignen Melanom The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network Knochenmarkssuppression nach Kombinationstherapie mit Rhenium-186 Hydroxyethylidenphosphonat (HEDP) und hyperbarem Sauerstoff im Tiermodell

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Carmen Loquai (1974-)

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Second opinion and self‐efficacy in German skin cancer patients

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

eHealth literacy in German skin cancer patients

Evaluation of 2‑methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma

Gibt es eine Überbehandlung von Melanompatienten am Ende ihres Lebens? : : Ergebnisse einer multizentrischen Studie an 193 Melanompatienten = Is there an overtreatment of melanoma patients at the end of their life? : results of a multicenter study on 193 <br>melanoma patients

Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : : a retrospective multicenter study

Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis

Erfassung der psychosozialen Belastung und Lebensqualität beim malignen Melanom

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Knochenmarkssuppression nach Kombinationstherapie mit Rhenium-186 Hydroxyethylidenphosphonat (HEDP) und hyperbarem Sauerstoff im Tiermodell